Edyta Czepielewska

Dr. Edyta Czepielewska

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
ECEdyta Czepielewska
Edyta Czepielewska
MMMagdalena Makarewicz-Wujec
Magdalena Makarewicz-Wujec
FRFilip Różewski
Filip Różewski
EWElżbieta Wojtasik
Elżbieta Wojtasik
MKMałgorzata Kozłowska-Wojciechowska
Małgorzata Kozłowska-Wojciechowska

1 January 2017 in Archives of Medical Science
Verified
Journal Article
Open access
PDF file
KTKarol B. Tudrej
Karol B. Tudrej
ECEdyta Czepielewska
Edyta Czepielewska
MKMałgorzata Kozłowska-Wojciechowska
Małgorzata Kozłowska-Wojciechowska
Melanoma is one of the most dangerous and lethal skin cancers, with a considerable metastatic potential and drug resistance. It involves a malignant transformation of melanocytes. The exact course of events in which melanocytes become melanoma cells remains unclear. Nevertheless, this process is...

29 September 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ALAgnieszka Lisowska
Agnieszka Lisowska
ECEdyta Czepielewska
Edyta Czepielewska
MRMartyna Rydz
Martyna Rydz
ADAnna Dworakowska
Anna Dworakowska
MMMagdalena Makarewicz-Wujec
Magdalena Makarewicz-Wujec
MKMałgorzata Kozłowska-Wojciechowska
Małgorzata Kozłowska-Wojciechowska
Potentially inappropriate prescribing (PIP) is one of the major risk factors of adverse drug events in elderly patients. Pharmacotherapy assessment criteria may help reduce the instances of PIP among geriatric patients. This study aimed to verify the applicability of selected tools designed to assess prescribing appropriateness in elderly and to identify PIP in the study population. Based on pharmacist-led medication reviews that were performed among patients attending senior day-care centers based in Poland, aged 65 years and over, the following tools were applied for assessing the appropriateness of pharmacotherapy: PILA (patient-in-focus listing approach): STOPP/START v.2 and Amsterdam tool, DOLA (drug-oriented listing approach): PRISCUS list, and DOLA+: Beers criteria v.2019 and the EU(7)-PIM list–the criteria oriented on medications requiring indications. Fifty patients participated in the study. The prevalence of prescribing issues in the study population was very high and ranged from 28% to 100%, depending on the criteria applied. The highest number of PIP cases was identified based on the PILA criteria: STOPP/START v.2 (171, a mean of 3.4 PIP cases per patient), and the Amsterdam criteria (124, a mean of 2.5 PIP cases per patient). The lack of protective vaccinations against pneumococci identified using the START criterion was found to be the most common PIP (identified in 96% of the patients). Proton-pump inhibitors (PPIs) were identified as the most problematic group of medications. The STOPP, EU(7)-PIM and Beers criteria revealed cases of inappropriate prolonged PPI use, whereas the Amsterdam tool identified cases where PPIs should have been prescribed but were not. The highest number of PIP cases in the study population were identified with the PILA tools, and on this basis the most comprehensive assessment of pharmacotherapy appropriateness in geriatric patients was conducted. Further studies should be designed, covering a larger group of patients across different healthcare settings (inpatient and outpatient), with access to comprehensive patient data.

12 April 2017 in Molecules
Verified
Journal Article
Open access
PDF file
AKAnita Kośmider
Anita Kośmider
ECEdyta Czepielewska
Edyta Czepielewska
MKMieczysław Kuraś
Mieczysław Kuraś
KGKrzysztof Gulewicz
Krzysztof Gulewicz
WDWioleta Dołomisiewicz
Wioleta Dołomisiewicz
Grażyna NowickaGrażyna Nowicka
Grażyna Nowicka
Uncaria tomentosa is a woody vine with a long history of use in traditional Peruvian medicine and nowadays supplements containing this vine as ingredient are available. Immunomodulating, anti-inflammatory and anticancer properties of Uncaria tomentosa have been suggested and attributed mainly to the presence of tetracyclic or pentacyclic oxindole alkaloids. However, the synergic action of different compounds occurring in extracts and modulation of redox processes may significantly influence the anticancer activity of Uncaria tomentosa. The aim of the present study was to investigate for the first time the cytotoxic effects of the tetracyclic alkaloids free aqueous extract (decoction) of dried Uncaria tomentosa leaf blades in normal and cancer cells, and to assess the effect of the tested extract on cisplatin (CDDP) cytotoxicity. Tested Uncaria tomentosa extract was not cytotoxic for NHDF cells, but demonstrated cytotoxic effect against HepG2 cells. The extract increased ROS production in HepG2 cells, which resulted in decreased GSH level, leading to apoptosis of these cells through activation of caspase-3 and caspase-7. A reduction of NF-κB active form was observed in cancer cells. In normal cells the extract did not affect ROS production, GSH level and NF-κB activity, and maintained cell viability. HepG2 cells incubation with Uncaria tomentosa decoction and simultaneously with CDDP resulted in an increase in CDPP cytotoxic activity against HepG2, while under the same conditions Uncaria tomentosa prevents NHDF cell viability reduction due to CDDP. The results indicate that Uncaria tomentosa leaves decoction modulates differently cancer and normal cells oxidative metabolism and, enhanced cytotoxicity of CDDP against cancer cells and at the same time increased normal healthy cells resistance to cisplatin. Further studies are needed to confirm our observations and to describe underlying molecular mechanism, and the potential usefulness of Uncaria tomentosa decoction in adjuvant therapy for cancer.

1 November 2018 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MPMarta Polkowska
Marta Polkowska
PEPaweł Ekk-Cierniakowski
Paweł Ekk-Cierniakowski
ECEdyta Czepielewska
Edyta Czepielewska
MKMałgorzata Kozłowska-Wojciechowska
Małgorzata Kozłowska-Wojciechowska

20 October 2016 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
MPMarta Polkowska
Marta Polkowska
ECEdyta Czepielewska
Edyta Czepielewska
MKMałgorzata Kozłowska-Wojciechowska
Małgorzata Kozłowska-Wojciechowska